New immunotherapy combo made available for patients with advanced anal cancer
NCT ID NCT06910137
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This program provides retifanlimab, an immunotherapy drug, together with standard chemotherapy (carboplatin and paclitaxel) to adults with advanced squamous cell carcinoma of the anal canal who cannot join other clinical trials. The goal is to offer a potential treatment option when no others are available. Participants must be in reasonably good health and have no other suitable therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- retifanlimab (a type of immunotherapy) combined with carboplatin and paclitaxel (chemotherapy)
- What this could lead to
- If this works, it could offer a treatment option for people with advanced anal cancer who have run out of standard choices.
- What could go wrong
- This is an early access program, not a formal trial, so effectiveness and safety are still being studied. It may not work for everyone and can cause side effects like immune reactions or chemotherapy toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.